Delving into the Latest Updates on Brentuximab Vedotin with Synapse

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Sequence Code 9923046L

Source: *****

Sequence Code 13006940H

Source: *****

This phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). In addition, the phase III trial will compare the effect of pembrolizumab after HDT-ASCT to standard of care HDT-ASCT alone in high-risk patients with relapsed or refractory classic Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. An ASCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving HDT before an ASCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Radiation therapy (RT) uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving brentuximab vedotin and nivolumab after radiation may be safe, tolerable and more effective than standard of care HDT-ASCT in treating patients with standard risk relapsed or refractory classic Hodgkin lymphoma. In addition, giving pembrolizumab after standard of care HDT-ASCT may be safe and tolerable and more effective than HDT-ASCT alone in treating high-risk patients with relapsed or refractory classic Hodgkin lymphoma.

Start Date04 Dec 2026

Sponsor / Collaborator

National Cancer Institute

NCT07275216

/ RecruitingPhase 2IIT

Phase 2 Study of Pembrolizumab With Chemotherapy in Frail Patients With Newly Diagnosed Classical Hodgkin Lymphoma

This phase II trial tests how well pembrolizumab in addition to chemotherapy (gemcitabine, brentuximab vedotin, and dacarbazine) works in treating frail patients with newly diagnosed Hodgkin lymphoma who aren't candidates for standard anthracycline-based treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. Dacarbazine is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells and slow down or stop cancer growth. Pembrolizumab in combination chemotherapy may be a safe and effective alternative treatment option for frail patients with Hodgkin lymphoma who can't receive standard anthracycline-based treatment.

Start Date01 Oct 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07717580

/ Not yet recruitingPhase 2IIT

A Phase II, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in Patients With CD30-positive Cutaneous T-cell Lymphoma (CTCL)

This is a prospective, single-center, open-label, randomized, controlled phase II clinical trial. The main purpose of this study is to evaluate the efficacy and safety of combining brentuximab vedotin (an anti-CD30 antibody-drug conjugate, ADC) with lisaftoclax (APG-2575, a novel B-cell lymphoma 2 (BCL-2) inhibitor) in patients with CD30-positive cutaneous T-cell lymphoma (CTCL), specifically including mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL).
Previous studies suggest that the overexpression of the anti-apoptotic protein BCL-2 may contribute to brentuximab vedotin resistance in CTCL. Researchers hypothesize that adding a highly selective BCL-2 inhibitor (lisaftoclax) can reverse this drug resistance, enhance tumor cell apoptosis, and improve clinical outcomes.
In this study, approximately 46 eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment arms:
Monotherapy arm (control): Patients will receive brentuximab vedotin intravenously at a dose of 1.8 mg/kg every 3 weeks for a total of 16 cycles.
Combination arm (experimental): Patients will receive the same brentuximab vedotin regimen. Additionally, starting from the 6th cycle, patients will receive oral lisaftoclax. To mitigate the risk of tumor lysis syndrome (TLS), a daily dose ramp-up will be implemented in the first cycle of lisaftoclax. Subsequently, lisaftoclax will be administered at a targeted dose of 600 mg daily on days 1 to 10 of each 21-day cycle, for a total of 9 combination cycles.
The primary endpoint of the study is the objective response rate (ORR) evaluated at the end of the 16 cycles. Secondary endpoints include the improvement of skin lesions (evaluated by modified severity-weighted assessment tool (mSWAT) score), pruritus relief (visual analog scale (VAS) score), and the incidence of adverse events (AEs). Independent, blinded assessors will be utilized to evaluate the clinical responses to reduce bias.

Start Date31 Jul 2026

Sponsor / Collaborator

Peking University First Hospital

[+1]

100 Clinical Results associated with Brentuximab Vedotin

Login to view more data

100 Translational Medicine associated with Brentuximab Vedotin

Login to view more data

100 Patents (Medical) associated with Brentuximab Vedotin

Login to view more data

1,719

Literatures (Medical) associated with Brentuximab Vedotin

31 Dec 2026·Hematology

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study

Article

Author: Alaboud, Mashael S. ; Al Sulaiman, Khalid ; As Sobeai, Homood M. ; Bakr, Abrar ; Alotaibi, Amal H. ; Abumustafa, Areej ; Alghamdi, Abrar ; Alkhudair, Nora ; Alrajhi, Abdullah M. ; AlHaj Issa, Arwa ; Alayaf, Badr ; Alalawi, Mai ; Alzahrani, Mohammed ; Alshehri, Bashayer ; Alenazi, Abeer A. ; Vishwakarma, Ramesh ; Alsuhebany, Nada ; Alshahrani, Walaa A. ; Alyousif, Ghadah ; AlHaj Issa, Zahra ; Alateeq, Abdullah

OBJECTIVE:

Hodgkin lymphoma (HL) constitutes 3.4% of all cancers in Saudi Arabia, with advanced-stage relapse rates reaching 40%. While the anti-CD30 agent brentuximab vedotin (BV) has established efficacy, local data are limited. This study aims to assess the real-world effectiveness and safety of Brentuximab vedotin (BV)-containing regimens compared to non-BV regimens in relapsed or refractory classical Hodgkin lymphoma (cHL) in Saudi Arabia.

METHODS:

A retrospective, multicenter cohort study was conducted including 93 adult patients with relapsed or refractory cHL in Saudi Arabia between 2016 and 2021. Patients were categorized into a BV-containing group (n = 61) and a control group (n = 32). The outcomes were overall response rate (ORR), complete response (CR), event-free survival (EFS), and post-chemotherapy complications.

RESULTS:

= The BV group showed a higher ORR compared to the non-BV group (82.5% vs. 76.9%), although this difference was not statistically significant (adjusted odds ratio [aOR] = 9.09; 95% CI = 0.67-122.57; P = 0.10). CR rates were comparable between the two groups, at 59.6% in the BV group vs. 61.5% in the control group (aOR = 1.86; 95% CI = 0.24-14.46; P = 0.55). EFS was significantly longer in the BV group compared with the control group in the crude analysis (22.5 vs. 11.2 months; P = 0.03); however, this finding did not reach statistical significance in the regression analysis (beta coefficient = 7.04; 95% CI = -2.96 to 17.03; P = 0.18). Post-chemotherapy complications were comparable and not statistically significant across both groups.

CONCLUSION:

The research indicates that BV may offer a potential clinical advantage for patients with relapsed or refractory cHL. To validate these findings and optimize treatment strategies for this population, larger long-term studies with expanded patient cohorts are required.

01 Dec 2026·JAAD international

Outcomes of brentuximab vedotin in cutaneous T-cell lymphoma: A Middle Eastern real-world study

Article

Author: Boalbanat, Hashem ; Elkady, Dina ; Rajy, Jihan ; Alsarraf, Ahmad ; Pinto, Karen ; Tawab Hamed, Rasha Abdel

01 Dec 2026·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Artificial intelligence for anticancer drug discovery from natural products of macroalgae and sponges: A systematic review

Review

Author: Hernawan, Ari ; Sunarwidhi, Anggit Listyacahyani ; Rahmaniar, Wahyu

Marine natural products (MNPs) from macroalgae and marine sponges have inspired clinically important anticancer agents, including the cytarabine pharmacophore and the eribulin scaffold, while cyanobacterial dolastatin chemistry supplies the auristatin payloads of several marine-inspired antibody-drug conjugates (ADCs) such as brentuximab vedotin. Artificial intelligence (AI) methods, encompassing both classical machine learning (ML) with hand-engineered features and modern deep learning (DL) with many-layered neural networks, are increasingly supporting key decisions in natural-product anticancer drug discovery, including bioactivity prediction, target identification, absorption, distribution, metabolism, excretion and toxicity (ADMET) filtering, generative analogue design, and the selection of preclinical candidates. DL architectures relevant to this field include graph neural networks, transformer-based molecular generators, diffusion models for protein-ligand docking, and convolutional networks for mass spectrometry, while classical ML contributes interpretable fingerprint-based bioactivity models and molecular networking for dereplication. This review follows a systematic literature review methodology to organize the landscape of AI methods now applied to MNP anticancer discovery, distinguishing ML and DL approaches where relevant, situating them within the chemical context of macroalgal and sponge-derived oncology leads, and critically examining published case studies, including validation level (computational, in vitro, in vivo, clinical). The principal bottleneck for medical translation has shifted partly from algorithmic capability toward data infrastructure and experimental validation. Sparse, heterogeneous, and taxonomically biased bioactivity records limit what current models can learn and reduce the reliability of AI-prioritized candidates entering the preclinical pipeline. A roadmap is proposed that prioritizes open MNP-specific benchmarks, symbiont-aware modeling, and active learning loops with synthesizability and ADMET constraints. These AI workflows may accelerate the prioritization of marine-derived anticancer leads and support earlier, more evidence-based translational decisions in oncology drug development.

264

News (Medical) associated with Brentuximab Vedotin

16 Oct 2026

·www.prnewswire.com

TORL BioTherapeutics Strengthens Leadership Team with Appointments of Proven Industry Leaders

Sandip Kapadia appointed Chief Financial Officer with more than 30 years of life sciences experience in growth strategy, capital formation and commercial execution Eric Sievers, M.D., appointed Chief Medical Officer with more than 30 years of experience leading oncology clinical and translational research with a focus on antibody-drug conjugates LOS ANGELES, Oct. 16, 2026 /PRNewswire/ -- TORL BioTherapeutics LLC ("TORL" or the "Company"), a clinical-stage oncology company, today announced the appointments of Sandip Kapadia as Chief Financial Officer and Eric Sievers, M.D., as Chief Medical Officer. These appointments complete a year-long strategic initiative to expand and strengthen TORL's leadership team as the Company advances its novel portfolio of antibody-based therapeutics toward late-stage development and potential commercialization. Mr. Kapadia brings more than 30 years of life sciences experience with a strong track record in growth strategy, capital formation and commercial execution. Most recently, he served as Chief Financial and Administrative Officer at Harmony Biosciences during its transition to a profitable commercial-stage biotechnology company. He has raised more than $2 billion in public capital for emerging biotechnology companies. Dr. Sievers's career spans more than three decades of clinical and translational research, with expertise in antibody-drug conjugates (ADCs) for hematologic malignancies and solid tumors. Most recently, he served as Chief Medical Officer at BioAtla. His experience includes first-in-human studies, pivotal trials and regulatory submissions. Earlier in his career, he led clinical development of ADCETRIS from Investigational New Drug (IND) through initial Food and Drug Administration (FDA) approval. Dr. Sievers also served as a lead investigator in the first-in-human and pivotal trials supporting the initial approval of MYLOTARG. "We are delighted to welcome Sandip and Eric to TORL at this important stage in our evolution. Together, they bring decades of leadership experience across the life sciences industry and a proven track record of advancing new therapeutics," said Aran Maree, M.D., Chief Executive Officer. "Sandip's strategic and financial leadership will be instrumental as we enter our next phase of growth, organizational scale and late-stage clinical development for our lead asset ixotatug vedotin (Ixo-V). Eric's experience advancing antibody therapeutics from early clinical development through regulatory approval will be invaluable as we advance Ixo-V and our broader pipeline. Their combined expertise further strengthens our ability to execute on the significant opportunity ahead. We look forward to working together as a leadership team to deliver on our mission to transform the lives of cancer patients with novel antibody-based therapies." Separately, TORL announced that Mark Alles retired as Chairman of the Board at the end of September. Since joining TORL in 2022, Mr. Alles served in various leadership roles including as Board Manager, Chief Executive Officer and Chairman. During his tenure, he led the Company through a period of significant financial, clinical, and organizational growth and development. Mr. Alles will remain a strategic advisor to the Company. "Mark has played an important role in TORL's evolution over the past several years," said Dr. Maree. "On behalf of the Board and management team, I want to thank him for his leadership, counsel and commitment to the Company. We are grateful that he will continue to support TORL as a strategic advisor." About TORL BioTherapeutics LLC TORL BioTherapeutics is a clinical-stage oncology company developing antibody-based therapeutics against first-in-world targets for solid tumors and hematologic cancers. Lead asset ixotatug vedotin (Ixo-V; TORL-1-23) is the first and only ADC that selectively targets Claudin 6 (CLDN6) with a proven monomethyl auristatin E (MMAE) linker-payload construct. Ixo-V is being evaluated in platinum-resistant ovarian cancer and other CLDN6-expressing cancers such as germ cell tumors and in various combinations. Ixo-V has been granted FDA Fast Track designation. The early pipeline includes the Phase 1 hematology asset TORL-5-700 and other undisclosed programs. TORL's unique discovery engine is enabled by a strategic partnership with the Slamon Research Lab at the University of California, Los Angeles (UCLA), which provides preferential access to novel cancer targets for therapeutic development. To date, TORL has raised more than $450 million from leading global biotechnology investors. SOURCE TORL Biotherapeutics LLC 21% more press release views with Request a Demo

Phase 1Executive ChangeADCFast Track

04 Sep 2026

·www.biospace.com

Pfizer punts Seagen ADC, further muddying value of the $43B buyout

iStock, cagkansayin The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of the pharma. Pfizer has cast off another asset from it’s $43 billion dollar acquisition of Seagen, with the pharma this time signing over primary responsibility for an investigational antibody-drug conjugate to Medicus Pharma. Medicus has agreed to pay $12 million upfront for the asset, dubbed PF-08046031, according to a Sept. 2 SEC filing . The Pennsylvania biotech is also on the hook for a one-time $15 million payment on the first anniversary of the agreement, as well as certain development, regulatory and sales milestones that could bring the total deal value past $1 billion if realized. Pfizer could also receive tiered royalties on annual net sales of the antibody-drug conjugate (ADC). Despite ceding authority to Medicus, Pfizer appears to want to retain a substantial degree of control in the development of PF-08046031. Under the terms of the license agreement, the pharma gave Medicus a one-time, non-refundable $2 million commitment to kickstart its activities for the ADC therapy, which the biotech is “required to apply solely to fund” PF-08046031. Pfizer will also receive Medicus’ development plans for the asset and “has the right to review and comment on those plans” as well as meet with the biotech’s team to discuss PF-08046031, according to the securities document. Medicus is also required to submit “periodic progress reports” for the program to Pfizer. Deals Pfizer Wins Seagen Sweepstakes with $43B Bid Pfizer will acquire the Seattle-based antibody-drug conjugate leader in a $43 billion deal expected to close late in 2023 or early 2024. March 13, 2023 · 1 min read · Kate Goodwin Read more The star of the deal, PF-08046031, is an early-stage ADC that targets melanotransferrin , a known antigen associated with melanoma that has since also been linked to other solid tumors. The molecule joined the Pfizer fold in 2023, with the pharma’s massive acquisition of Seagen. Despite some early clinical successes—including a Phase 3 win in March 2024 for the ADC Adcetris in diffuse large B cell lymphoma—the confidence in Pfizer’s Seagen gamble has grown shakier in recent years. In June, a closely watched ADC sigvotatug vedotin delivered disappointing performance in a Phase 3 non-small cell lung cancer study, unable to significantly boost overall survival versus docetaxel. Then, a few weeks later, Pfizer quietly axed SGN-MesoC2, another Seagen-linked asset that the pharma had been developing for solid tumors. As a Pfizer subsidiary, Seagen ran a Phase 1 study of SGN-MesoC2. But the disquiet over the Seagen acquisition started much earlier. Activist investor Starboard Value cited the takeover as one of the reasons behind its challenge to the pharma’s leadership, according to an October 2024 presentation that has since been taken down. Starboard also took issue with Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics, which similarly dealt several clinical disappointments . Pfizer “significantly overpaid” for both of these deals, the investor said at the time.

Phase 1ADCAcquisitionLicense out/inPhase 3

10 Aug 2026

·www.pharmaceutical-technology.com

Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III

Innate will now progress its CTCL asset, lacutamab, to a confirmatory Phase III trial in the condition. Credit: Dermatology11 / Shutterstock.com. The Swedish Orphan Biovitrum, or Sobi, has inked a licensing deal worth up to $580m with Innate Pharma for its cutaneous T-cell lymphoma (CTCL) hopeful, lacutamab, amid an accelerated approval submission. Under the terms of the deal, Sobi will hand $75m upfront to help Innate begin the confirmatory Phase III TELLOMAK-3 study in CTCL, which the latter hopes will back lacutamab’s potential full approval in two CTCL subtypes: Sézary syndrome and mycosis fungoides. In exchange, Innate will offer Sobi the exclusive global rights to commercialise lacutamab provided it secures accelerated approval, as well as the worldwide development rights to the drug if Phase III results are positive. On top of the upfront sum, Sobi has also committed to hand over $40m in potential near-term development milestones associated with lacutamab’s Sézary programme, as well as up to $465m if the company chooses to secure the full development rights to the drug alongside future regulatory and commercial milestones. Sobi will offer Innate double-digit royalties on any resulting lacutamab sales if the drug makes it to market. This comes as Innate eyes an accelerated approval for lacutamab in Sézary syndrome, a rare and aggressive variant of CTCL, based on a win from the Phase II TELLOMAK study (NCT03902184). In the trial, lacutamab prompted durable responses and favourable safety in a heavily pre-treated patient population. Lacutamab, a first-in-class medicine, acts as an anti-killer-cell immunoglobulin-like receptor 3DL2 (KIR3DL2), which helps to control immune cell activity and is often overexpressed in patients with CTCL. The therapy has already received Fast Track and PRIME designations from US and European regulators, respectively. According to Innate’s CEO, Jonathan Dickinson, the advancement of lacutamab into a Phase III study marks a “pivotal moment” for the company as it looks to secure a place on the oncology market. However, the company is not just pinning its hopes on lacutamab, Dickinson notes, as it is also expecting key milestones for its Nectin-4-targeting antibody-drug conjugate (ADC), IPH4502, and its immune checkpoint inhibitor, monalizumab, which he says represent “important developments” for Innate in 2026. Treating CTCL CTCL is a rare form of non-Hodgkin lymphoma caused by the accumulation of abnormal T-cells in the skin – leaving patients with itchy skin afflictions that often look like rashes, psoriasis or eczema. In recent years, there have been multiple advancements in the treatment of CTCL, with the approval of drugs like Pfizer-owned Seagen and Takeda’s Adcetris (brentuximab vedotin), as well as Amneal Pharmaceuticals’ romidepsin injection solution in 2024 and June 2026, respectively. However, several drugs have failed to cross the line to regulatory approval in CTCL, with a dedicated Phase II trial for Karyopharm Therapeutics’ selinexor being put on ice due to challenges around enrolment. Meanwhile, 4SC also failed to secure the European Medicines Agency’s (EMA) blessing despite its drug, Kinselby (resminostat), meeting its primary endpoint in the Phase II RESMAIN study (NCT02953301), due to the drug’s perceived lack of benefit to warrant approval. Most recently, Soligenix opted to terminate its development programme for topical CTCL therapy, HyBryte, after a data monitoring committee deemed it unlikely the drug would meet its primary goals in a pivotal Phase III trial. Currently, researchers estimate that the global incidence of primary cutaneous lymphomas (PCL), a category which includes CTCL, is one in 100,000.

Phase 2Phase 3Fast TrackLicense out/inDrug Approval

100 Deals associated with Brentuximab Vedotin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09587	Brentuximab Vedotin	L01FX05	DB08870

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diffuse Large B-Cell Lymphoma	United States	Seagen, Inc.	11 Feb 2025
High grade B-cell lymphoma	United States	Seagen, Inc.	11 Feb 2025
CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma	Japan	Takeda Pharmaceutical Co., Ltd.	24 Nov 2023
Classical Hodgkin's Lymphoma	United States	Seagen, Inc.	09 Nov 2017
Mycosis Fungoides	United States	Seagen, Inc.	09 Nov 2017
Primary Cutaneous Anaplastic Large Cell Lymphoma	United States	Seagen, Inc.	09 Nov 2017
Cutaneous T-Cell Lymphoma	Australia	Takeda Pharmaceuticals Australia Pty Ltd.	20 Dec 2013
Peripheral T-Cell Lymphoma	Australia	Takeda Pharmaceuticals Australia Pty Ltd.	20 Dec 2013
CD-30 positive Peripheral T-Cell Lymphoma	South Korea	Takeda Pharmaceuticals Korea Co., Ltd.	16 May 2013
CD30+ Hodgkin's Lymphoma	European Union	Takeda Pharma A/S	25 Oct 2012
CD30+ Hodgkin's Lymphoma	Iceland	Takeda Pharma A/S	25 Oct 2012
CD30+ Hodgkin's Lymphoma	Liechtenstein	Takeda Pharma A/S	25 Oct 2012
CD30+ Hodgkin's Lymphoma	Norway	Takeda Pharma A/S	25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma	European Union	Takeda Pharma A/S	25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma	Iceland	Takeda Pharma A/S	25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma	Liechtenstein	Takeda Pharma A/S	25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma	Norway	Takeda Pharma A/S	25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma	European Union	Takeda Pharma A/S	25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma	Iceland	Takeda Pharma A/S	25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma	Liechtenstein	Takeda Pharma A/S	25 Oct 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
CD-30 positive Lymphoma	Phase 3	-	Takeda Pharmaceutical Co., Ltd.	01 Jan 2024
Primary mediastinal large B-cell lymphoma recurrent	Phase 3	-	Takeda Pharmaceutical Co., Ltd.	01 Jan 2024
Diffuse large B-cell lymphoma recurrent	Phase 3	United States	Seagen, Inc.	20 Aug 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	Australia	Seagen, Inc.	20 Aug 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	Belgium	Seagen, Inc.	20 Aug 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	Canada	Seagen, Inc.	20 Aug 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	Czechia	Seagen, Inc.	20 Aug 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	Denmark	Seagen, Inc.	20 Aug 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	France	Seagen, Inc.	20 Aug 2020
Diffuse large B-cell lymphoma recurrent	Phase 3	Italy	Seagen, Inc.	20 Aug 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04404283 (ECHELON-3, CTgov)	Phase 3	Diffuse large B-cell lymphoma recurrent	240	Lenalidomide+Rituximab+Brentuximab Vedotin (Brentuximab Vedotin + Lenalidomide + Rituximab)	ecywsythmx(ugznwlbtrd) = gdizusjkrp nihjermjir (oravtrhlwt, rqcbztlrcd - pjvwsnkfvo) View more	-	21 Oct 2026
NCT04404283 (ECHELON-3, CTgov)	Phase 3	Diffuse large B-cell lymphoma recurrent	240	Lenalidomide+Placebo+Rituximab (Placebo + Lenalidomide + Rituximab)	ecywsythmx(ugznwlbtrd) = cnxkvbygwc nihjermjir (oravtrhlwt, jhanoxnsak - ixxkbecctw) View more	-	21 Oct 2026
CSCO2026	Not Applicable	Hodgkin's Lymphoma	132	BV + PD-1 inhibitor + chemotherapy	botzjenwxw(hifknvpjdn) = Most adverse events were grade 1-2, with a low incidence of grade 3-4 adverse events. The most common adverse events were neutropenia (42.1%), elevated transaminases (32.2%), and thrombocytopenia (28.9%). Notably, the incidence of grade ≥ 3 peripheral neuropathy was low (2.5%). yajtmytxem (yzclxkoccf )	Positive	11 Sep 2026
CSCO2026	Not Applicable	Hodgkin's Lymphoma	132	BV + PD-1 inhibitor		Positive	11 Sep 2026
CSCO2026	Not Applicable	Lymphoma	91	Brentuximab vedotin-based therapy	dgawljiiqx(jtxiaozjxr) = Increased visceral adiposity (HR =16.08, P=0.017), and reduced skeletal muscle mass (HR =5.44, P=0.010) independently predicted poorer survival. jsapzmgsib (omkdbmqczt ) View more	Positive	11 Sep 2026
NCT03409432 (CTgov)	Phase 2	Lymphomatoid Papulosis \| Primary Cutaneous Anaplastic Large Cell Lymphoma \| T-cell lymphoma refractory ... View more	26	Laboratory Biomarker Analysis+Lenalidomide+Brentuximab Vedotin	btkjnghrvy = wszigdkbuj gkhtpmirnq (ueuvokvvsg, nsidupfwbs - ijgyagocyy) View more	-	13 Aug 2026
NCT01657331 (SGN+Benda, CTgov)	Phase 1/2	Refractory Hodgkin Lymphoma \| Anaplastic Large-Cell Lymphoma	65	Bendamustine+Brentuximab Vedotin (Phase 1)	arzsfvzqsu = dfkhziaaqd lryhqzgygj (ihlnpjpaxt, staujwaszq - rqaccwjhuv) View more	-	24 Jun 2026
NCT01657331 (SGN+Benda, CTgov)	Phase 1/2		65	Bendamustine+Brentuximab Vedotin (Phase 1: Brentuximab Vedotin 1.2 mg/kg, Bendamustine 70 mg/m^2)	pksvjknpra = qrfequebcy bwgyaykhkr (gyfajrdhmz, vzcynavwup - biesithtkj) View more	-	24 Jun 2026
NCT05673785 (CTgov)	Phase 2	Peripheral T-Cell Lymphoma \| CD-30 positive Peripheral T-Cell Lymphoma	52	Cyclophosphamide+Prednisone+Doxorubicin+Brentuximab Vedotin	ohbqkoodkl = fecfadnfgn rsxelssvkd (zxolwuiwqi, qaipfpyujk - ubqvyxlzqc) View more	-	12 Jun 2026
EULAR2026	Not Applicable	Scleroderma, Systemic	10	Brentuximab vedotin (severe diffuse cutaneous systemic sclerosis)	jdkxdeecac(xsxgpbfbbc) = 5 patients had mRSS worsening (≥6 points) and 5 remained relatively stable uheaqdqenu (zsztxpxnkc ) View more	Positive	11 Jun 2026
NCT05006664 (CHEPA, ASCO2026)	Phase 2	Peripheral T-Cell Lymphoma CD30-positive	33	Brentuximab vedotin plus CHEPA	kekrefmxbj(mbhpqpxmfx) = wfobbpbnch yonhtxozbj (ezxrnalmzg ) View more	Positive	29 May 2026
NCT05006664 (CHEPA, ASCO2026)	Phase 2	Peripheral T-Cell Lymphoma CD30-positive	33	Brentuximab vedotin plus CHEPA (ALCL)	kekrefmxbj(mbhpqpxmfx) = nuxerydhzc yonhtxozbj (ezxrnalmzg ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Refractory Classic Hodgkin Lymphoma	315	Nivolumab plus Brentuximab Vedotin	odwfbrojio(efpcmpdsbz) = ddmtkqxebs bgoqcqsqli (xmlkpqhkkv, 56.4 - 68.2) View more	Positive	29 May 2026
NCT01476410 (CTgov)	Phase 2	Hodgkin's Lymphoma \| Nodular Sclerosis Classical Hodgkin Lymphoma	49	RNA analysis+Dacarbazine+fludeoxyglucose F 18+doxorubicin hydrochloride+vinblastine+brentuximab vedotin	cuvlyqoxhn = azcyxbntmu uoqghewsrd (cltrhchipd, edrmnlnctt - xecilayzmc) View more	-	22 May 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Brentuximab Vedotin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation